GlassScriptPhysician profile
Maisoon Torfah
NPI 1275053191
$2,025.40
in general payments reported to CMS, 2019-2025
22 companies · $1,133 in 2025
The $1,133 reported for 2025 was more than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $318 · 2024: $575 · 2025: $1,133.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,876 · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,875.86 |
| Education | $149.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $414.00 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $260.78 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Medtronic, INC. | $233.46 | 2023-2025 | Minimed 780g |
| Tandem Diabetes Care, INC. | $183.32 | 2023-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Corcept Therapeutics | $166.63 | 2024-2025 | Korlym |
| Mannkind Corporation | $103.11 | 2025 | |
| Dexcom, INC. | $79.97 | 2023-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.04 | 2024-2025 | Jardiance |
| Amgen INC. | $70.59 | 2025 | Evenity, Prolia, Tepezza |
| Abbott Laboratories | $70.03 | 2023-2025 | Freestyle Libre 3 |
| Ascendis Pharma Endocrinology INC | $66.53 | 2025 | Yorvipath |
| Radius Health, INC. | $59.90 | 2024-2025 | Tymlos |
| Amneal Pharmaceuticals LLC | $50.52 | 2024-2025 | Unithroid |
| Sequel Med Tech, LLC | $39.72 | 2025 | Twiist |
| Antares Pharma, INC. | $24.24 | 2024 | Xyosted |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $20.45 | 2024 | |
| Abbvie INC. | $19.10 | 2023 | Vraylar |
| Boston Scientific Corporation | $18.69 | 2023 | Wavewriter Alpha Prime 16 |
| Ascensia Diabetes Care US INC. | $18.66 | 2024 | |
| Acella Pharmaceuticals, LLC | $17.67 | 2025 | NP Thyroid 60 |
| Recordati_rare_diseases_inc. | $16.79 | 2025 | Isturisa |
| Cequr Corporation | $16.20 | 2024 | Cequr Simplicity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maisoon Torfah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.